News

Sera Prognostics’ PreTRM® Test Wins 2016 Utah Innovation Award in Life Sciences

First-in Class Novel Commercial Blood Test to Predict Early, Accurate, Individualized Risk for Premature Birth

SALT LAKE CITY, May 12, 2016 -- Sera Prognostics, Inc., a women’s health company, today announced that it was selected as the 2016 Utah Innovation Award winner in the Life Science – BioTech category for its novel PreTRM® test, a clinical blood test for early, individualized risk assessment of premature birth.

Landmark Study Published in American Journal of Obstetrics & Gynecology Validates New Blood Test as Objective, Predictive Tool for Preterm Birth Risk

The PreTRM® Test is Now Commercially Available to Predict Risk Early in Pregnancy

SALT LAKE CITY, March 10, 2016 – Sera Prognostics, Inc., a women’s healthcare company, today announced that clinical validation data from the 5,501 patient Proteomic Assessment of Preterm Risk (PAPR) study were published online in the American Journal of Obstetrics & Gynecology.

New Survey Reveals Untapped Opportunity to Improve Sales Effectiveness for Life Sciences Industry

Zephyr Health Report Explores the Rise of Insights-Driven Customer Relationships

SAN FRANCISCO, March 8, 2016 – Today Zephyr Health, the leading Insights-as-a-Service company, released a report that reveals a largely untapped opportunity for sales teams in Life Sciences companies; integrating global health data and predictive insights into their commercial efforts.

Positive Clinical Validation Data for PreTRM® Test Presented at the Society for Maternal-Fetal Medicine’s 36th Annual Pregnancy Meeting

Sera Prognostics’ Novel Proteomic PreTRM Test Enables Early, Objective
Prediction of Preterm Birth Risk

SALT LAKE CITY, Feb. 4, 2016 – Sera Prognostics, Inc., a women’s healthcare company, today announced that results from the 5,501-patient Proteomic Assessment of Preterm Risk (PAPR) study validate the newly available PreTRM® test, which accurately and objectively predicts spontaneous preterm birth (sPTB), in pregnant women as early as 19 weeks.

Sera Prognostics to Present at 34th Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, December 21--Sera Prognostics, Inc., a women’s healthcare company, today
announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming J.P. Morgan Healthcare Conference. Dr. Critchfield’s presentation will take place at 9:30 AM PT on Thursday, January 14, 2016 at the Westin St. Francis Hotel in San Francisco, CA.

About Sera Prognostics, Inc.

Sera Prognostics to Present at 27th Annual Piper Jaffray Healthcare Conference

Sera Prognostics to Present at 27th Annual Piper Jaffray Healthcare Conference

SALT LAKE CITY, November 24--Sera Prognostics, Inc., a women’s healthcare company, today
announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the Piper Jaffray Healthcare Conference . Dr. Critchfield’s presentation will take place at 10:30 AM ET on Wednesday, December 2, 2015 at the Lotte New York Palace Hotel in New York, NY.

About Sera Prognostics, Inc.